Skip to main content

Allakos Inc. (ALLK)

NASDAQ: ALLK · IEX Real-Time Price · USD
77.60 1.29 (1.69%)
Dec 8, 2021 4:00 PM EST - Market closed
Market Cap4.21B
Revenue (ttm)n/a
Net Income (ttm)-219.77M
Shares Out54.31M
EPS (ttm)-3.58
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume373,169
Open76.85
Previous Close76.31
Day's Range75.62 - 78.25
52-Week Range70.37 - 157.98
Beta0.88
AnalystsBuy
Price Target143.10 (+84.4%)
Earnings DateNov 8, 2021

About ALLK

Allakos Inc. operates as a clinical stage biopharmaceutical company. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic esophagitis. The is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. Allakos Inc. was incorporated in 2012 and is headqu...

IndustryBiotechnology
IPO DateJul 19, 2018
CEORobert Alexander
Employees167
Stock ExchangeNASDAQ
Ticker SymbolALLK
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for Allakos stock is "Buy." The 12-month stock price forecast is 143.10, which is an increase of 84.41% from the latest price.

Price Target
$143.10
(84.41% upside)
Analyst Consensus: Buy

News

Allakos Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma

– Phase 2 Atopic Dermatitis trial of subcutaneous lirentelimab initiated –– Phase 2/3 Chronic Spontaneous Urticaria trial of subcutaneous lirentelimab to begin in mid 2022 –– Phase 2 Asthma trial of sub...

1 week ago - GlobeNewsWire

Do Options Traders Know Something About Allakos (ALLK) Stock We Don't?

Investors need to pay close attention to Allakos (ALLK) stock based on the movements in the options market lately.

2 weeks ago - Zacks Investment Research

Allakos Provides Business Update and Reports Third Quarter 2021 Financial Results

REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell...

1 month ago - GlobeNewsWire

Allakos Presents Data at ACG 2021 from Prospective Study Showing High Prevalence Rates of Eosinophilic Gastritis and/...

– Study shows 45% (181/405) of patients with moderate-to-severe unexplained gastrointestinal symptoms who underwent upper endoscopy with biopsy met the histologic criteria for eosinophilic gastritis and...

1 month ago - GlobeNewsWire

Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the American College ...

REDWOOD CITY, Calif., Oct. 24, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell...

1 month ago - GlobeNewsWire

3 Biotech Stocks With Huge Catalysts Incoming

These drugmakers have big events that should occur before the end of 2021.

Other symbols:BYSIDCPH
1 month ago - The Motley Fool

Implied Volatility Surging for Allakos (ALLK) Stock Options

Investors need to pay close attention to Allakos (ALLK) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

Allakos Provides Business Update and Reports Second Quarter 2021 Financial Results

REDWOOD CITY, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell...

3 months ago - GlobeNewsWire

3 Biotech Stocks That Could Double Soon

Wall Street analysts following these drugmakers think they can produce big gains in a short time frame.

Other symbols:AFMDDCPH
4 months ago - The Motley Fool

Allakos Completes Patient Enrollment in Phase 3 Eosinophilic Gastritis and/or Eosinophilic Duodenitis and Phase 2/3 E...

-- Results from both clinical trials expected in the fourth quarter of 2021 -- -- CMO Dr. Henrik Rasmussen to retire; Dr. Craig Paterson, SVP of Clinical Development and Medical Affairs, promoted to CMO --

6 months ago - GlobeNewsWire

Moving Average Crossover Alert: Allakos (ALLK)

Allakos (ALLK) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

6 months ago - Zacks Investment Research

New Allakos Data Presented at DDW 2021 Suggest that Eosinophilic Gastritis and/or Eosinophilic Duodenitis (EG/EoD) is...

45% (181/405) of patients with chronic functional gastrointestinal symptoms who underwent upper endoscopy with biopsy met the diagnostic criteria for eosinophilic gastritis and/or eosinophilic duodeniti...

6 months ago - GlobeNewsWire

Bear Of The Day: Allakos (ALLK)

Bear Of The Day: Allakos (ALLK)

6 months ago - Zacks Investment Research

7 of the Best Pharma Stocks to Buy Now

As the market gets back to normal, it's a great time to explore the pharma stocks that got lost in the vaccine frenzy of the past year. The post 7 of the Best Pharma Stocks to Buy Now appeared first on ...

6 months ago - InvestorPlace

Allakos Reports First Quarter 2021 Financial Results and Provides Business Update

REDWOOD CITY, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-...

6 months ago - GlobeNewsWire

Allakos Appoints Baird Radford as Chief Financial Officer

REDWOOD CITY, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil...

7 months ago - GlobeNewsWire

Are Options Traders Betting on a Big Move in Allakos (ALLK) Stock?

Investors need to pay close attention to Allakos (ALLK) stock based on the movements in the options market lately.

11 months ago - Zacks Investment Research

Allakos Appoints Natalie Holles to its Board of Directors

REDWOOD CITY, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related disease...

11 months ago - GlobeNewsWire

Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update

REDWOOD CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell...

1 year ago - GlobeNewsWire

Allakos Announces Pricing of Public Offering of Common Stock

REDWOOD CITY, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseas...

1 year ago - GlobeNewsWire

Allakos Previews Preliminary Financial Results for the Three Months Ended September 30, 2020

REDWOOD CITY, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK) (“Allakos” or “the Company”), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell r...

1 year ago - GlobeNewsWire

Allakos Announces Proposed Public Offering of Common Stock

REDWOOD CITY, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseas...

1 year ago - GlobeNewsWire

Allakos Announces Results from a Phase 1 Study of Subcutaneously Administered Lirentelimab (AK002)

-- Subcutaneous formulation of lirentelimab was safe and well tolerated and demonstrated sustained eosinophil suppression support ing once monthly dosing -- -- Management to host conference call and web...

1 year ago - GlobeNewsWire

Allakos Announces Publication of Results from the Phase 2 Study of Lirentelimab (AK002) in Patients with Eosinophilic...

REDWOOD CITY, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related disease...

1 year ago - GlobeNewsWire

Allakos Reports Second Quarter 2020 Financial Results and Provides Business Update

REDWOOD CITY, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell-related dise...

1 year ago - GlobeNewsWire